BioSpace News Archive

Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually on Tuesday, January 12, 2021 at 5:20 PM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that it will be presenting at the SNN Network Canada Virtual Event on Thursday, January 7, 2021 at 4:00 p.m. E

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, announced that the first patient was dosed in late December 2020 in a Phase 1 clinical trial of VIR-1111, an investigational human immunodeficiency virus (HIV) T cell vaccine. VIR-1111 is a proof-of-concept vaccine designed to test the hypothesis that this new approach can elicit potentially protective immune

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is pleased to announce the appointment of Manuel Zafra as the new Managing Director for Canada.

AbbVie (NYSE: ABBV) will participate in the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 . Members of AbbVie’s executive leadership team will present virtually at 3:30 p.m. Central time , including Richard A. Gonzalez , chairman of the board and chief executive officer, Michael Severino , M.D

Panalgo’s IHD software to be used by the EMA to rapidly answer questions around drug safety and efficacy and better understand real-world medication use

Omega Therapeutics, Inc. (“Omega”), a development-stage biotechnology company pioneering the field of Epigenomic Programming™ to precisely regulate and control the human genome to treat and cure disease, today announced that Mahesh Karande , President and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Heal

Elevation Oncology , a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today that Shawn M. Leland , PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology, will present at the 39 th Annual J.P. Morgan Healthcare Confere

- AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. The technology is covered by four patent applications already on file with the United States Patent and Trademark Office.

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced that president and chief executive officer Fred Chereau will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 4:30 pm ET . Mr. Chereau will provide an overview of com